Klygefa (gefurulimab) approved in the US

Summary by AI BETAClose X

Klygefa (gefurulimab) received FDA approval for adult anti‑AChR+ generalised myasthenia gravis after the PREVAIL Phase III trial (N=260) showed a primary endpoint improvement in MG‑ADL versus placebo with a treatment difference of −1.6 (95% CI −2.4 to −0.8; p<0.0001), with clinical benefit from week 1 and sustained through one year; safety was consistent with C5 inhibitors (TEAEs similar to placebo; injection‑site reactions 12%, back pain 8%, vomiting 5%). Klygefa is the first US dual‑binding nanobody C5 inhibitor offering once‑weekly subcutaneous autoinjector dosing, targets an estimated US AChR‑positive population of 81,000, and is already approved in the EU and Japan with further filings underway.

Disclaimer*

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings